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ABSTRACT. Investment is an interesting thing to analyze during the Corona Virus Disease 
(COVID-19) pandemic because at this time the economy is experiencing a decline so specifically 
for investors, they must consider the level of risk in their shares. The purpose of this study is to 
determine the condition of Consumer Goods Industry stocks with a concentration of 
pharmaceutical companies that can form an optimal portfolio and to determine the proportion of 
each selected stock and the level of return and risk of the resulting portfolio. The method that 
used is Single Index Model approach. The results of the analysis show that using the Single Index 
Model, Consumer Goods Industry stocks with a concentration of pharmaceutical companies from 
December 2016 to November 2020 can form an optimal portfolio consisting of SIDO with a 
proportion of 26.10%, PYFA with a proportion of 23 , 02%, DVLA with a proportion of 50.89% 
and a portfolio expected return of 5.79% and a risk of 6.95%. 
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Investing in the capital market has a high risk. To reduce risk, investors can analyze the company's 
financial health through financial reports as well as analyze stock values and calculate stock returns 
from previous years. Compiling a portfolio can also be an alternative to reduce risk through stock 
diversification. In compiling a stock portfolio, the analysis carried out by investors needs to be 
more thorough and in-depth so that investors need to carry out a portfolio analysis. Portfolio 
analysis will assist investors in making decisions to determine which portfolio is the most efficient 
that has the highest expected rate of return with the least risk. 
The author tries to analyze stock portfolios in one of the industries listed on the Indonesia Stock 
Exchange, namely the Consumer Goods Industry with a concentration of pharmaceutical 
companies. This industry was chosen because companies engaged in the pharmaceutical industry 
are currently experiencing very significant developments related to the Covid-19 pandemic. The 
Corona Virus Disease (COVID-19) pandemic has resulted in increased consumption of medicines 
and the use of vitamins. Thus, this study will reveal the expected rate of return in the 
pharmaceutical industry and also determine the best portfolio structure. In this study the authors 
limit the problem to the formation of 9 securities portfolios from the consumer good industry 
sector with a concentration of pharmaceutical companies on the Indonesia Stock Exchange. The 
data used is data on monthly share price movements of 9 securities from December 2016 to 
November 2020. 
The model used in this research is the Markowitz model. Markowitz model tries to maximize 
portfolio expected return for a given amount of portfolio risk, or homogeneously minimize risk 
for a given level of expected return, with the correct proportions of various securities. This model 
presumes that investors are rational and markets are efficient, tends to illustrate an asset’s return 
as a normally distributed random variable, identifies risk as the standard deviation of return, and 
demonstrates a portfolio. By combining different assets whose returns are not perfectly positively 
correlated, modern portfolio theory seeks to reduce the total variance of the portfolio return. This 
model looks for reduction of the total variance of the portfolio return, by combining different 
assets whose returns are not perfectly positively (Markowitz, 1952). Calculations were performed 
using the Single Index Model. The purpose of this study is to determine the expected average level 
of return and risk of each security and to provide an overview of the most efficient portfolios. 
 
METHODS 
This study aims is to determine which stocks are eligible to be included in the formation of an 
optimal portfolio using the Single Index Model on consumer good industry stocks with a 
concentration of pharmaceutical companies from December 2016 to November 2020 on the 
Indonesia Stock Exchange.  
The data used in this study is secondary data in the form of stock prices of companies listed in the 
consumer good industry with a concentration of pharmaceutical companies on the Indonesia Stock 
Exchange. Secondary data is data that is not collected and is not processed independently but is 
obtained through other people, from companies, or institutions related to research. For example, 
the Indonesia Stock Exchange can be accessed through www.idx.co.id. 
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The population used in this study were shares of pharmaceutical companies that were included in 
the consumer good industry from December 2016 to November 2020, namely 12 companies. The 
sample in this study were 9 companies obtained using purposive sampling method with the criteria 
of consumer good industry stocks with a concentration of pharmaceutical companies that always 
appeared consecutively during the observation period December 2016 to November 2020. 
The data method used in this study is the non-behavioral observation method, namely observations 
made without involving oneself and only as independent observations. Data is collected from the 
the official website of the Indonesia Stock Exchange (IDX), namely www.idx.co.id. 
The variable that used in this study consists of: 
Stock Return 
Stock return is the rate of return obtained from the amount of investment in stocks and can be 
calculated using a formula (Jogiyanto, 2014 : 265) 
 
𝑹𝒊 =
(𝑷𝒕 − 𝑷𝒕 − 𝟏)
𝑷𝒕 − 𝟏
 
Ri : Return from stock i 
Pt : Price in t period 
Pt-1 : Prices in the previous period 
 
Market Return 
Market return is the rate of return obtained from investing in all shares on the stock exchange 
where the shares are reflected in the Composite Stock Price Index (IHGS) (Jogiyanto, 2014: 408): 
 
𝑹𝒎 =
(𝑰𝒕 − 𝑰𝒕 − 𝟏)
𝑰𝒕 − 𝟏
 
Rm : Market Return 
It : Observation period market index 
It-1 : Market index in the previous period 
 
Expected Stock Return 
Expected Return is the return that investors expect to be able to generate by the investment they 






E(Ri) : Expected Return stock i 
Rit : Return stock i 
n : Total observation 
 
Market Expected Return 
Market expected return is the return expected by investors to be generated by the market and can 







E(Rm) : Market Expected Return 
Rmt : Market return on t period 
n : Total observation 




Market risk is the difference between the expected market return and the market return and can 








σm2 : Market Return Variance 
Rmt : Market return on t period 
E(Rm) : Market Expected Return 
n : Total observation 
 
Beta 
Beta is a coefficient that measures the effect of market returns on changes that occur in stock 
returns. Beta can be calculated by first calculating the covariance between market returns and stock 
returns using the formula (Jogiyanto, 2014: 452) 
 




σim : Covariance between stock i return and market return 
Ri : Return stock i 
E(Ri) : Expected Return Stock i 
Rm : Market Return 
E(Rm) : Expected Market Return 
 
Alpa 
Alpha is a variable that is not influenced by return and can be calculated with the formula (Bodie 
et.al, 2002: 295): 
 
𝒂𝒊 = 𝑬(𝑹𝒊) − 𝜷𝒊. 𝑬(𝑹𝒎) 
ai : Stock i alpha 
(Rm) : Market Expected Return 
Rm : Market Return 
 
The variance of the residual error 
The variance of the residual error is a variable that shows the presence of unsystematic risks that 
occur within the company and can be calculated using the formula (Bodie et.al, 2002: 295): 
 
𝝈𝒆𝒊2 = 𝝈𝒊2 − 𝜷𝒊2𝜷𝒊. 𝝈𝒎2)  
𝜎𝑒𝑖2 : The variance of the residual error 
𝜎𝑖2 : Variance Return stock i 
βi : Stock i beta 
𝜎𝑚2 : Market Return Variance 
 
Excess Return to Beta (ERB) 
The level of Excess Return to Beta (ERB) can be calculated with the formula (Jogiyanto, 2014: 
430): 
 







ERBi : Excess Return to Beta stock i 
E(Ri) : Expected Return stock i 
Rbr : Return of stock assets i 
βi : Stock i beta 
 
Cut off rate (Ci) 
Cut off Rate (Ci) is the limiting point used to determine whether a stock can be included in the 
portfolio or not. The selected stocks are with CI ≤ ERb. Before calculating Ci, you must calculate 






E(Ri) : Expected Return Stock i 
Rbr : Return of stock assets i 
βi : Beta stock i 






βi : Beta stock i 
σei2 : The variance of the residual error 
 
After obtaining the values of Ai and Bi, then Ci can be calculated using the formula (Jogiyanto, 
2014: 431): 
Calculating the amount of the proportion of funds is done after the portfolio is formed, calculated 





(𝑬𝑹𝑩𝒊 − 𝑪 ∗) 
Wi : Proportion of shares to i 
k : the number of shares in the portfolio 
βi : Stock i beta 
σei2 : The variance of the residual error 
ERBi : Excess Return to Beta stock i 
C* : Cut off Points, which is the largest Ci value 
 
Expected Return Portfolio 
Portfolio Expected Return can be calculated with the formula (Jogiyanto, 2014: 424): 
 
𝑬(𝑹𝒑) = 𝜶𝒑 + 𝜷𝒑. 𝑬(𝑹𝒎) 
E(Rp) : Portfolio Expected Return  
αp : the weighted average of negligence per security 
βp : the weighted average of the beta of each security 















Meanwhile, risk can be calculated by (Kewal 2013) 
σp2  : Portfolio Variance 
βp. σm2 : Market related risk 
Wi2. σei2 : weighted average of each firm's unsystematic risk 
 





RESULT AND DISCUSSION 
To answer the objectives, the first research was carried out by collecting stock price data at closed 
price and IHSG for the period December 2016-November 2020, as well as the reference interest 
rate as a risk-free profit rate. 
Share price data when closed priced is processed by subtracting the stock price this month from 
the previous month (repeated) and then averaged. The result is the average expected rate of return. 
Furthermore, the annual interest rate data is divided by 12 to become a risk reference per month. 
Stock systematic risk (βi) is obtained from calculating the slope of the linear regression line (slope) 
through the data points of stock return i and IHSG return. 
The results of data processing are described in table 1  
 
Table 1. Average Expected Return dan Risiko Sistematis Saham 2017-2020 




1 DVLA Darya-Varia Laboratoria Tbk 0,0092 0,1698 
2 INAF Indofarma (Persero) Tbk 0,0590 -0,0389 
3 KAEF Kimia Farma (Persero) Tbk 0,0325 -0,8523 
4 KLBF Kalbe Farma Tbk 0,0018 0,7438 
5 MERK Merck Tbk -0,0080 0,8266 
6 PYFA Pyridam Farma Tbk 0,0454 0,7227 
7 SIDO Industri Jamu dan Farmasi Sido 
Muncul Tbk 
0,0373 0,0582 
8 TSPC Tempo Scan Pacific Tbk -0,0060 0,8620 
9 SDPC 
Millennium Pharmacon 
International Tbk                                       
0,0033 0,3439 
Source: data processed (2021) 
The formation of a portfolio using the Single Index Model can be done in the following steps: The 
first step that must be done is to determine the stock rating based on the excess return to beta 
(ERB) ratio, by subtracting the expected return of each stock by the risk free level, and the result 
divided by the beta of the relevant stock is shown in Table 2. 
 





Table 2.  Expected Return and Excess Return to beta (December 2016 - November 2020) 
No Stock Code Company E® ERBi 
1 DVLA Darya-Varia Laboratoria Tbk 0,005172 0,030445 
2 INAF Indofarma (Persero) Tbk 0,054922 -1,40932 
3 KAEF Kimia Farma (Persero) Tbk 0,028394 -0,03331 
4 KLBF Kalbe Farma Tbk -0,0023 -0,00309 
5 MERK Merck Tbk -0,01207 -0,0146 
6 PYFA Pyridam Farma Tbk 0,041313 0,057161 
7 SIDO Industri Jamu dan Farmasi Sido Muncul Tbk 0,033213 0,570586 
8 TSPC Tempo Scan Pacific Tbk -0,01007 -0,01168 
9 SDPC Millennium Pharmacon International Tbk                                       -0,00075 -0,00217 
Source: data processed (2021) 
Based on the results of Table 2, it can be seen that those with the largest excess return to beta 
(ERB) value are shares of the Sido Muncul Herbal Medicine and Pharmaceutical Industry 
company. (SIDO) of 0.570586 and the smallest is Indofarma (Persero) Tbk. (INAF) of -1.40932. 
Furthermore, the shares that are included in the portfolio are separated optimal and stocks that do 
not meet the requirements in the Optima portfolio, using the existing formula can be determined 
the value of Ci for each share. Furthermore, through the Ci obtained, the cut off point (C *) will 
be determined, which is the largest Ci value shown in Table 3. 
 
Table 3. Cut Off Rate dan Cut Off Point 
No Stock Code α β 0 ERB Ci C* 
1 SIDO 0,0372 0,0582 0,0283 0,5706 0,0001 0,0013 
2 PYFA 0,0441 0,7228 0,0391 0,0572 0,0013 0,0013 
3 DVLA 0,0089 0,1699 0,0022 0,0304 0,0007 0,0013 
4 SDPC 0,0027 0,3440 0,0063 -0,0022 -0,0001 0,0013 
5 KLBF 0,0005 0,7438 0,0051 -0,0031 -0,0005 0,0013 
6 TSPC -0,0075 0,8620 0,0067 -0,0117 -0,0019 0,0013 
7 MERK -0,0094 0,8266 0,0359 -0,0146 -0,0005 0,0013 
8 KAEF 0,0339 -0,8524 0,0787 -0,0333 -0,0005 0,0013 
9 INAF 0,0591 -0,0390 0,1867 -1,4093 0,0000 0,0013 
Source: data processed (2021) 
In Table 3. It can be seen that the Ci value of the shares that are spread is the Ci value of Pyridam 
Farma Tbk. (PYFA) shares, which is 0.0013, so the cut off point (C *) of the stocks that will form 
a portfolio is 0.0092 then after the value of C * is determined, a selection of stocks that can be 
used as candidates is made to form an optimal portfolio by comparing the ERB of each stock with 

















Company ERB Ci C* Decision 
1 SIDO 
Industri Jamu dan Farmasi Sido 
Muncul Tbk 
0,5706 0,0001 0,0013 Optimal 
2 PYFA Pyridam Farma Tbk 0,0572 0,0013 0,0013 Optimal 




-0,0022 -0,0001 0,0013 - 
5 KLBF Kalbe Farma Tbk -0,0031 -0,0005 0,0013 - 
6 TSPC Tempo Scan Pacific Tbk -0,0117 -0,0019 0,0013 - 
7 MERK Merck Tbk -0,0146 -0,0005 0,0013 - 
8 KAEF Kimia Farma (Persero) Tbk -0,0333 -0,0005 0,0013 - 
9 INAF Indofarma (Persero) Tbk -1,4093 0,0000 0,0013 - 
Source: data processed (2021) 
From Table 4. It can be seen that the stock of companies with an ERB value greater than C * is 
the Sido Muncul Tbk Herbal Medicine and Pharmacy Industry. (SIDO), Pyridam Farma Tbk. 
(PYFA), Darya-Varia Laboratoria Tbk. (DVLA) therefore these shares can be referred to as 
candidate stocks in order to form an optimal portfolio. After the candidate stocks that can form 
the optimal portfolio have been determined, the next step is to determine the proportion of each 
share in the optimal portfolio as shown in Table 5. 
 




Company ERB Wi 
1 SIDO Industri Jamu dan Farmasi Sido Muncul Tbk 0,5706 26,10% 
2 PYFA Pyridam Farma 0,0572 23,02% 
3 DVLA Darya-Varia Laboratoria Tbk 0,0304 50,89% 
Total 100,00% 
Source: data processed (2021) 
Based on Table 5. It can be seen that the funds invested in each of the selected stocks, namely: 
Sido Muncul's Herbal Medicine and Pharmaceutical Industry Tbk. (SIDO) with a proportion of 
26.10%, Pyridam Farma Tbk. (PYFA) with a proportion of 23.02%, Darya-Varia Laboratoria Tbk. 
(DVLA) with a proportion of 50.89%. The final stage in calculating the optimal portfolio is 
calculating the amount of excpected return and optimal portfolio variance as shown in Table 6. 
 









1 SIDO Industri Jamu dan Farmasi Sido Muncul Tbk 0,0033 0,0283 
2 PYFA Pyridam Farma 0,0454 0,0391 
3 DVLA Darya-Varia Laboratoria Tbk 0,0092 0,0022 
Total 0,0579 0,0696 
Source: data processed (2021) 
From Table 6. It can be seen that in the period December 2016 to November 2020 investment in 
SIDO, PYFA, DVLA, as a portfolio capable of generating returns of 5.79% and a risk of 6.95%. 





Based on the results of calculations and discussion carried out, the following conclusions can be 
obtained, namely: 
1. Stocks that can be selected to form an optimal portfolio using the Single Index Model of 12 
consumer good industry stocks with the concentration of pharmaceutical companies are as 
many as 3 stocks with each proportion, namely: the Herbal Medicine and Pharmacy Industry 
Sido Muncul Tbk. (SIDO) with a proportion of 26.10%, Pyridam Farma Tbk. (PYFA) with a 
proportion of 23.02%, Darya-Varia Laboratoria Tbk. (DVLA) with a proportion of 50.89%. 
2. The rate of profit (excpected return) is 5.79% with a risk (variance) of 6.95%. 
Based on the analysis results and conclusions, some suggestions can be given as follows: 
1. Investors who want to invest in the Indonesian capital market, especially in consumer good 
industry shares with a concentration of pharmaceutical companies, should invest very carefully 
by choosing stocks that are included in the optimal portfolio, such as Sido Muncul Tbk's Herbal 
and Pharmaceutical Industry (SIDO). 
2. For the next researcher who wants to try to form an optimal portfolio by using the Single Index 
Model on consumer good industry stocks with a concentration of pharmaceutical companies, 
adjustments should be made using the latest data on consumer good industry stocks with a 
concentration of pharmaceutical companies. 
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